VA-REGULA
29.2.2024 08:01:32 CET | Business Wire | Press release
Regula's expansion has been notably significant in three key markets: the United States, the United Arab Emirates, and Great Britain, which collectively account for over 35% of its global user base. The growth rates in these regions have been particularly impressive: United States – 216%; United Arab Emirates – 321%; United Kingdom – 95%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228514546/en/
Growth Trends: Regula User Expansion & Verification Scenarios in Key Markets (Graphic: Business Wire)
Not only do these figures highlight Regula's increasing prominence in these markets, but also underscore the global trust in the company’s technologies for secure and reliable identity verification. What sets Regula apart is its independence from third-party solutions, with all technologies developed internally. Regula offers a single-vendor solution for identity verification, combining biometric (Regula Face SDK) and document (Regula Document Reader SDK) checks with advanced authenticity validation, as well as forensic tools for detailed analysis.
The rise of full authenticity checks
The results of the survey conducted by Regula at the beginning of 2023 highlight an increase in identity fraud. The most prevalent form of fraudulent activity experienced by organizations was the use of fake or modified physical documents. 26% of small and medium businesses (SMBs) and 38% of enterprises experienced more than 50 identity fraud incidents during the previous year. The cost was also significant, with 64% of all businesses reporting losses of at least $120,000, and 37% of the world’s largest businesses reporting losses of at least $480,000.
In response to the evolving landscape of digital fraud, Regula has intensively focused on enhancing its techniques aimed at validating document authenticity. Its advanced authentication method facilitates verification of ID security features, as well as document liveness validation. This processing scenario has seen astounding growth rates in the United States (367%), United Arab Emirates (400%), and United Kingdom (86%).
Strengthening security with cross-validation
Regula also reports a steady increase in the adoption of its cross-validation checks, which provide maximum confidence in the consistency and authenticity of identity document data. These checks help ensure data integrity by cross-comparing personal details or biometric information provided on an identification document.
Growth rates in this area are equally remarkable: United States – 156%, United Arab Emirates – 257%, United Kingdom – 244%.
Regula's extensive proprietary database, which includes more than 13,600 document templates from 249 countries and territories and supports over 138 languages, is central to the success of these checks.
Diverse user engagement across platforms
A key advantage of Regula's identity verification solutions is their compatibility across various platforms, allowing for seamless ID verification processes, whether on mobile, web, desktop, or passport reading devices.
The company's success is demonstrated through its provision of hardware and software solutions for digital identity verification, serving a worldwide network of more than 1,000 organizations and 80 border control authorities. Some of the world's most innovative and reputable organizations rely on Regula’s hardware and software solutions to solve a range of challenges. For example:
- UBS, the largest private bank in the world, has applied a robust customer onboarding system thanks to Regula’s comprehensive identity verification solutions.
- FREENOW, a Mobility Super App, employs a set of Regula solutions to enable proper taxi driver identity verification to secure its ride-hailing services.
- WizzAir and AirAsia use Regula solutions to expedite flight onboarding.
- The Portuguese Immigration and Border Service has facilitated travel document verification by developing a mobile app based on Regula Document Reader SDK.
- Pearson VUE, a global online testing giant, identifies users with the help of Regula technologies to grant admission to remotely administered professional exams.
"In this fiercely competitive market, it is imperative for all vendors to maintain a razor-sharp focus on delivering unwavering value to their users, ensuring that their services become indispensable components of daily operations," remarked Henry Patishman, Executive VP of Identity Verification Solutions at Regula. "Leveraging our deep-rooted expertise in both hardware and software, coupled with our strong and enduring connections within the forensic community, Regula has crafted a unique proposition. This combination of cutting-edge technology and forensic expertise allows us to deliver a deeply enriching experience for a wide range of applications to streamline onboarding and prevent identity fraud. Consequently, we have witnessed robust user adoption, a testament to our strategic investment in creating solutions that not only meet but exceed the expectations of our users in today’s dynamic environment."
For more information about Regula and its services, please visit Regula's website.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228514546/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
